Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial

Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial

Background Immunoglobulin A nephropathy (IgAN) is the most common cause of glomerulonephritis worldwide, and the optimal approach to its treatment remains a significant challenge. Methods We did a prospective, randomized, open-labeled, multicenter, controlled trial, comprised of 3-month run-in, 12-m...

Full description

Bibliographic Details
Main Authors: Zhaohui Ni, Zhen Zhang, Zanzhe Yu, Fuming Lu, Changlin Mei, Xiaoqiang Ding, Weijie Yuan, Wei Zhang, Gengru Jiang, Min Sun, Liqun He, Yueyi Deng, Huihua Pang, Jiaqi Qian
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Renal Failure
Subjects:
iga nephropathy
leflunomide
glucocorticoids
disease progression
proteinuria
Online Access:http://dx.doi.org/10.1080/0886022X.2021.1963775

Internet

http://dx.doi.org/10.1080/0886022X.2021.1963775

Similar Items